This is the most recent version of the national Cancer Drugs Fund list, and replaces any earlier versions. It contains updates to the previous list, as well as new drugs and indications which have ...

Praxis Precision Medicines has had an impressive performance over the last one year. Read why I remain neutral on PRAX stock.

Unfortunately, there is no test to diagnose essential tremor. A diagnosis is based on a neurological exam, which generally includes getting a medical history, as well as a history of the symptoms and ...

Parkinson’s disease is a condition that damages dopamine-producing brain cells, leading to tremors, stiffness, and difficulty with balance and coordination. Medications for Parkinson’s disease aim to ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

An adverse reaction is an undesirable reaction to a medication that's been taken correctly. These might include minor side effects like mild heartburn or life-threatening issues such as heart failure.

Sage Therapeutics said Biogen has terminated the companies' license agreement with respect to its SAGE-324 molecule, a investigational drug targeting essential tremor and epilepsy. The move comes ...

Bio­gen is say­ing good­bye to part of its tie-up with Sage Ther­a­peu­tics af­ter the duo’s ex­per­i­men­tal med­i­cine failed a Phase 2 es­sen­tial … ...

The Centers for Medicare & Medicaid Services Oct. 9 released a request for information and a sample list of prescription drugs it intends to include under a proposed Medicare $2 Drug List Model. Under ...

Sterile fluid supply: Like many medical facilities across the nation, our supply chain is feeling the effects of Hurricane Helene’s aftermath. Johns Hopkins Medicine currently has a sufficient sterile ...

The FDA and Lilly did not immediately respond to requests for comment. Mounjaro had been on the FDA's list of drugs in short supply since late 2022, while Zepbound was added in April. Compounding ...

Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after ...